How many different versions of gilitinib are currently on the market?

Gilitinib is an oral FLT3 inhibitor, mainly used to treat relapsed or refractory FLT3 mutant acute myeloid leukemia (AML). At present, the drug has been approved for marketing in China, but it has not yet been included in the national medical insurance directory, making it difficult to purchase it in domestic hospitals. Many patients still need to obtain the drug through overseas channels. This situation leaves patients facing a trade-off between drug accessibility and financial burden, so it is important to understand the different versions of giritinib available on the market.

There are currently three main versions of giritinib on the market: the European version of the original drug, the Hong Kong version of the original drug, and the generic drug produced in Laos. Among them, the original drug is developed and produced by Japan's Astellas (Astellas) company and is widely sold in Europe, the United States, Hong Kong, China and other regions. The Hong Kong version of gilitinib is extremely expensive due to high import and distribution costs. One box costs up to about 100,000 yuan, which is a heavy burden for most patients. The price of the European original version is slightly lower than the Hong Kong version, but it is still not an economical choice.

In contrast, the Laotian generic version of giritinib offers hope to many patients with limited financial resources. Companies such as Laos Lucius Pharmaceutical Factory (Luzhou/Health Biotech, etc.) have launched generic drugs with stable quality. The ingredients and efficacy of the drugs are basically the same as the original drugs. The price of generic drugs is close to the people, usually between one thousand and two thousand yuan, which significantly reduces the financial pressure on patients. This is especially true for patients who require long-term use or multi-cycle treatment.

In general, giritinib currently has two categories: original drugs and generic drugs on the market, including three main channel options: European original version, Hong Kong original version and Laos generic version. Patients should consider their own condition, financial ability and doctor's advice when making a choice. If it is difficult to continue treatment due to the high price of the original drug, choosing a reputable generic version can be a practical alternative. At the same time, it is recommended to obtain drugs through formal channels and use them under the guidance of a doctor to ensure the safety and effectiveness of treatment.

Reference materials:https://www.xospata.com/